Franz von Nussbaum

3.5k citations

59 papers · 2.0k indexed · 1 hit paper · h-index 23

Co-authors: Dieter Häbich Michael Brands Stefan Weigand Berthold Hinzen Samuel J. Danishefsky Dominik Mumberg Wölfgang Steglich Gerhard Siemeister
Topics: Microbial Natural Products and Biosynthesis (16 papers)Cancer-related Molecular Pathways (11 papers)Antibiotic Resistance in Bacteria (7 papers)
Cited by: Pharmacology Organic Chemistry Molecular Medicine
Journals: Angewandte Chemie International Edition Cancer Research Clinical Cancer Research
Partner nations: Germany United States France

In The Last Decade

Franz von Nussbaum

58 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival?

2006 530 citations Franz von Nussbaum, Michael Brands et al. Angewandte Chemie International Edition profile →

Peers

Countries citing papers authored by Franz von Nussbaum

Since Specialization

Citations

This map shows the geographic impact of Franz von Nussbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franz von Nussbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franz von Nussbaum more than expected).

Fields of papers citing papers by Franz von Nussbaum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franz von Nussbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franz von Nussbaum. The network helps show where Franz von Nussbaum may publish in the future.

Co-authorship network of co-authors of Franz von Nussbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Franz von Nussbaum. A scholar is included among the top collaborators of Franz von Nussbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franz von Nussbaum. Franz von Nussbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models 2021 ·Cellular Oncology ·Clara Lemos,Volker Schulze,Simon J. Baumgart,Ekaterina Nevedomskaya,Tobias Heinrich,Julien Lefranc,Benjamin Bader,Clara D. Christ,Hans Briem,Lara Kuhnke,Simon J. Holton,Ulf Bömer,Philip Lienau,Franz von Nussbaum,Carl F. Nising,Marcus Bauser,Andrea Hägebarth,Dominik Mumberg,Bernard Haendler	29
2	The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models 2019 ·Molecular Cancer Therapeutics ·Antje M. Wengner,Gerhard Siemeister,Ulrich Lücking,Julien Lefranc,Lars Wortmann,Philip Lienau,Benjamin Bader,Ulf Bömer,Dieter Moosmayer,Uwe Eberspächer,Sven Golfier,Christoph A. Schatz,Simon J. Baumgart,Bernard Haendler,Pascale Lejeune,Andreas Schlicker,Franz von Nussbaum,Michael Brands,Karl Ziegelbauer,Dominik Mumberg	145
3	Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo 2018 ·Clinical Cancer Research ·Gerhard Siemeister,Anne Mengel,Amaury E. Fernández‐Montalván,Wilhelm Bone,Jens Schröder,Sabine Zitzmann-Kolbe,Hans Briem,Stefan Prechtl,Simon J. Holton,Ursula Mönning,Oliver von Ahsen,(unknown),Arwed Cleve,Vera Pütter,(unknown),Franz von Nussbaum,Michael Brands,Karl Ziegelbauer,Dominik Mumberg	53
4	BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity 2017 ·Cancer Letters ·(unknown),Franziska Siegel,Antje M. Wengner,Claudia Lange,Ulf Bömer,Knut Eis,(unknown),Philip Lienau,(unknown),Martin Michels,Franz von Nussbaum,Dominik Mumberg,Kirstin Petersen	48
5	Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models 2017 ·Cancer Research ·(unknown),Julien Lefranc,Antje M. Wengner,Lars Wortmann,Hans Schick,Hans Briem,Gerhard Siemeister,Philip Lienau,Christoph A. Schatz,Benjamin Bader,(unknown),Franz von Nussbaum,Michael Brands,Dominik Mumberg,Karl Ziegelbauer	12
6	Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity 2016 ·Molecular Cancer Therapeutics ·Antje M. Wengner,Gerhard Siemeister,Marcus Koppitz,Volker Schulze,Dirk Kosemund,Ulrich Klar,Detlef Stoeckigt,Roland Neuhaus,Philip Lienau,Benjamin Bader,Stefan Prechtl,Marian Raschke,Anna-Lena Frisk,Oliver von Ahsen,Martin Michels,Bertolt Kreft,Franz von Nussbaum,Michael Brands,Dominik Mumberg,Karl Ziegelbauer	85
7	Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores 2015 ·Bioorganic & Medicinal Chemistry Letters ·Franz von Nussbaum,(unknown)	80
8	The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases 2014 ·European Respiratory Journal ·Johannes Nagelschmitz,(unknown),Stephan Schwers,Franz von Nussbaum,(unknown),Martina Delbeck,Klemens Lustig,Tiemo J. Bandel,Henrik Watz	5
9	The novel elastase inhibitor BAY 85-8501: First-in-man study to evaluate safety, tolerability and pharmacokinetics in healthy male subjects 2014 ·European Respiratory Journal ·Johannes Nagelschmitz,Michael Becka,(unknown),Stephan Schwers,Franz von Nussbaum,(unknown),Georg Wensing	2
10	Aspergillomarasmin A, ein Inhibitor bakterieller Metallo‐β‐Lactamasen vom bla _NDM ‐ und bla _VIM ‐Resistenztyp 2014 ·Angewandte Chemie ·Franz von Nussbaum,Guido Schiffer	2
11	Coloured Artefacts Formed by Oxidation of Benzene‐1,2,4‐triol and β‐Dopa During the Extraction of Cortinarius violaceus (Agaricales) with Alcohols 2011 ·European Journal of Organic Chemistry ·Franz von Nussbaum,Matthias Rüth,Peter Spiteller,(unknown),Florian Löbermann,Κ. Polborn,Wölfgang Steglich	3
12	Lost in Transcription—Inhibition of RNA Polymerase 2009 ·Angewandte Chemie International Edition ·Dieter Haebich,Franz von Nussbaum	23
13	Structure and Total Synthesis of Lysobactin (Katanosin B) 2007 ·Angewandte Chemie International Edition ·Franz von Nussbaum,(unknown),Jordi Benet‐Buchholz,Dieter Häbich,Johannes Köbberling,László Musza,(unknown),Helga Rübsamen‐Waigmann,Nina Brunner	38
14	Platensimycin, a New Antibiotic and “Superbug Challenger” from Nature. 2007 ·ChemInform ·Dieter Haebich,Franz von Nussbaum	2
15	Platensimycin, a New Antibiotic and “Superbug Challenger” from Nature 2006 ·ChemMedChem ·Dieter Häbich,Franz von Nussbaum	79
16	Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival?breakdown → 2006 ·Angewandte Chemie International Edition ·Franz von Nussbaum,Michael Brands,Berthold Hinzen,Stefan Weigand,Dieter Häbich	530
17	Alkaloids from marine organisms. Part 8: Isolation of bisdemethylaaptamine and bisdemethylaaptamine-9-O-sulfate from an Indonesian Aaptos sp. marine sponge 2004 ·Tetrahedron ·Anthony J. Herlt,Lewis N. Mander,(unknown),(unknown),(unknown),Wölfgang Steglich,(unknown),Franz von Nussbaum	25
18	Stephacidin B—A New Stage of Complexity within Prenylated Indole Alkaloids from Fungi 2003 ·Angewandte Chemie International Edition ·Franz von Nussbaum	71
19	Alkaloids from marine organisms. Part 7: Synthesis of bisdemethylaaptamine and bisdemethyloxyaaptamine—a biomimetic approach to the aaptamines? 2001 ·Tetrahedron ·Franz von Nussbaum,(unknown),Wölfgang Steglich	15
20	An Iron(III)-Catechol Complex as a Mushroom Pigment 1998 ·Angewandte Chemie International Edition ·Franz von Nussbaum,Peter Spiteller,Matthias Rüth,Wölfgang Steglich,(unknown),(unknown),Lorenzo Stievano,F. E. Wagner	29

About Franz von Nussbaum

Franz von Nussbaum is a scholar working on Molecular Medicine, Pharmacology and Cancer Research, having authored 59 papers that have together received 2.0k indexed citations. Recurring topics across this work include Microbial Natural Products and Biosynthesis (16 papers), Cancer-related Molecular Pathways (11 papers) and Antibiotic Resistance in Bacteria (7 papers). The work is most often cited by research in Pharmacology (490 citations), Organic Chemistry (809 citations) and Molecular Medicine (107 citations). Franz von Nussbaum has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Dieter Häbich, Michael Brands, Stefan Weigand, Berthold Hinzen, Samuel J. Danishefsky, Dominik Mumberg, Wölfgang Steglich, Gerhard Siemeister, Roderich D. Süßmuth and Philip Lienau. Their work appears in journals such as Angewandte Chemie International Edition, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact